Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Details for Australian Patent Application No. 2004269896 (hide)

Owner Gentium S.P.A.

Inventors Iacobelli, Massimo; Richardson, Paul; Ferro, Laura Iris

Agent Griffith Hack

Pub. Number AU-B-2004269896

PCT Pub. Number WO2005/023273

Priority 60/539,344 28.01.04 US; MI2003A001714 05.09.03 IT

Filing date 27 August 2004

Wipo publication date 17 March 2005

Acceptance publication date 19 November 2009

International Classifications

A61K 31/17 (2006.01) - having the group NC(O)N or NC(S)N, e.g. urea, thiourea, carmustine

A61K 31/195 (2006.01)

A61K 31/337 (2006.01) - having four-membered rings, e.g. taxol

A61K 31/665 (2006.01) - having oxygen as a ring hetero atom, e.g. fosfomycin

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

23 March 2006 PCT application entered the National Phase

  PCT publication WO2005/023273 Priority application(s): WO2005/023273

19 November 2009 Application Accepted

  Published as AU-B-2004269896

1 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004269897-Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

2004269892-1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses